title: Ontogenetic quinpirole treatment induces vertical jumping activity in rats.
abstract: Repeated ontogenetic treatment with quinpirole produces enhanced quinpirole-induced yawning and antinociceptive actions in adult rats. We now report the occurrence of a bizarre jumping behavior in rats so treated. Rats were treated daily from birth with quinpirole HCl (3.0 mg/kg per day x 28 days i.p., salt form) or saline vehicle. After each daily injection, the rats were observed for at least 1 h. Starting on the 18th day after birth, quinpirole treatment was associated with the appearance of jumping behavior. On the 20th day after birth a dose-effect relationship was found for quinpirole HCl (0.10-3.0 mg/kg), with maximal jumping activity occurring between 30 and 150 min after the 3.0 mg/kg dose. On the 26th day after birth, both spiperone HCl (0.30 mg/kg i.p.) and SCH 23390 HCl (0.30 mg/kg i.p.) attenuated the quinpirole effect. At 34 days the jumping response was virtually absent. The age-related jumping behavior appears to be another manifestation of the abnormal responses mediated by supersensitized dopamine receptors in quinpirole-primed rats. Based on the ability of dopamine D1 and D2 receptor antagonists to attenuate this effect, quinpirole-induced jumping behavior may be a reflection of cooperativity of dopamine D1 and D2 receptor types.
authors.affiliation: Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City 37614-0577.
authors.forename: R M
authors.initials: RM
authors.lastname: Kostrzewa
authors.forename: J
authors.initials: J
authors.lastname: Guo
authors.forename: F P
authors.initials: FP
authors.lastname: Kostrzewa
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000375:Aging; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001552:Benzazepines / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D009043:Motor Activity / Q000187:drug effects*; D019257:Quinpirole; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D013134:Spiperone / Q000494:pharmacology
chemical_list: D001552:Benzazepines; D015259:Dopamine Agents; D065127:Dopamine D2 Receptor Antagonists; D004873:Ergolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D013134:Spiperone; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine